Early intervention is key
Empowering patients to better protect themselves from severe allergic reactions that could lead to anaphylaxis. Anaphylaxis is a severe, life-threatening allergic reaction that could be fatal if not treated immediately.
An Alternative to Epinephrine Auto-Injectors
Successful dry powder inhalation
We are developing an epinephrine dry powder inhaler that for patients and their families could transform the treatment of allergic reactions potentially leading to anaphylaxis.
Some people may take a “watch and wait” approach to using an auto-injector.
ARS-1 is uniquely formulated with an absorption enhancing technology that has shown a comparable rate of epinephrine absorption to intramuscular injection with less risk of variability.
There is a fear of needles and stigma that leads to an unwillingness to use an auto-injector in public to treat severe allergic reactions. For parents or guardians, injecting a child may also be traumatic.
Small enough to carry in a pocket or purse anytime, anywhere.
PIMS-E, a Subsidiary of PureIMS, Announces Results of a Phase 1 Clinical Trial of Epinephrine Cyclops™, a Dry Powder Inhaler for Early Intervention in Allergic Reactions and Anaphylaxis
Delivery via single-inhaler could dramatically expand epinephrine’s clinical utility for
PIMS-E, a subsidiary of PureIMS, completes Dosing in Phase 1 Clinical Trial of Epinephrine Cyclops™, a Dry Powder Inhalation Device for Early Intervention in Allergic Reactions and Anaphylaxis
Delivery via inhaler could dramatically expand Epinephrine’s clinical utility for
Carduso Capital invests in PIMS-E
Carduso Capital invests in PIMS-E, a Spin-off company of the
Cyclops as example of the TopDutch pioneering and collaborating mentality
The Cyclops™ pre-loaded disposable dry powder inhaler is a product